Jacobio Pharma Shares Early Data on BET Inhibitor for Myelofibrosis at 2024 ASH

Jacobio Pharma, a company specializing in oncology treatments and listed under the ticker 1167.HK, has presented early Phase I data for its BET inhibitor JAB-8263, aimed at treating myelofibrosis (MF). This presentation took place at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, California.

The data revealed that JAB-8263 is well tolerated with a Recommended Phase 2 Dose (RP2D) of 0.3mg once daily. Preliminary efficacy results for JAB-8263 monotherapy in MF patients are promising, showing significant spleen volume reduction (SVR) and total symptom score (TSS) reduction in most patients. As of October 17, 2024, 16 patients with intermediate- to high-risk MF had been enrolled in the study, and 13 of these patients had undergone at least one post-treatment efficacy assessment.

The findings showed a mean SVR of -19.95% at week 24 and -26.16% at the best response. Two patients achieved a spleen volume reduction of 35% or greater, with one patient showing an SVR of -34.9%. Additionally, six out of ten patients experienced a reduction in TSS by 50% or more at week 24. For patients previously treated with JAK inhibitors, the best SVR responses were -41.2% and -34.9%, respectively. At week 24, half of these patients saw a 50% reduction in TSS.

The ongoing expansion of the JAB-8263 monotherapy trial aims to assess its effectiveness in both myelofibrosis and solid tumors. Dr. Andrea Wang-Gillam, Chief Medical Officer and Global Head of R&D at Jacobio, emphasized the potential clinical value of the BET inhibitor in treating MF. She mentioned the company's commitment to exploring broader indications for JAB-8263 to benefit more cancer patients.

Jacobio Pharma is dedicated to developing innovative oncology therapies, with a pipeline focused on novel molecular targets across six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC. The company aims to position its key projects among the top three in the world. With research and development centers located in Beijing, Shanghai, and Boston, Jacobio leverages its Induced Allosteric Drug Discovery Platform and iADC Platform to advance its mission of becoming a global leader in drug research and development.

Jacobio's vision is to make a significant impact in the field of drug R&D, working in partnership with other entities in the industry. The company's dedication to creating new and effective cancer treatments underscores its commitment to improving patient outcomes and advancing the field of oncology.